CDKN2A and neoplasm: In addition, multiplexing p16INK4a and Ki-67 in both SCC and adenocarcinoma (AC) can be a synergistic approach to quantitate each marker at a cellular level in tumor regions instead of the benign proliferative zones, thereby increasing diagnostic accuracy in both immunohistochemistry studies [25].